Based on these findings, we prospectively assessed if selecting cases with noncodon 12 KRAS/NRAS mutations and noncodon 600 BRAF mutation would increase the prevalence of POLE‐mutated MMR‐P CRC in the exonuclease domain compared with an unselected population. This evidence concerns the gene KRAS and colorectal carcinoma.